Can SGLT2 Inhibitors Protect Kidneys in Patients Without Diabetes?

Research-informed explainer — last updated April 12, 2026

A class of drugs originally developed to lower blood sugar in people with type 2 diabetes has turned out to be one of the most significant advances in kidney disease treatment in decades — and the benefit extends to people who don't have diabetes at all. The DAPA-CKD trial, published in the New England Journal of Medicine in 2020, showed that dapagliflozin (Farxiga) cut the combined risk of kidney failure, severe kidney function decline, and death from kidney or cardiovascular causes by 39% in patients with chronic kidney disease — including the roughly one-third of trial participants who had no diabetes whatsoever.

This matters because millions of people living with CKD may never have been offered these drugs. SGLT2 inhibitors carry the mental association of being diabetes medications, and many patients — and even some clinicians — haven't yet updated their mental model. If you have CKD with elevated protein in your urine and you're not taking an SGLT2 inhibitor, this article is worth reading before your next nephrology appointment.

This explainer draws on research from three nephrologists in the Convene directory. Glenn Chertow at Stanford University School of Medicine is Chief of Nephrology and co-author of the foundational 2004 study establishing the cardiovascular and mortality burden of CKD across the general population. He was also a contributing author on the DAPA-CKD trial itself. Richard Lafayette, also at Stanford, is Founder and Director of the Stanford Glomerular Disease Center and has led clinical trials in proteinuric kidney diseases — the specific patient population most likely to benefit from SGLT2 inhibitors. Emilio Poggio at the Cleveland Clinic has contributed foundational work on GFR estimation equations, the measurement tool used to assess kidney function and determine who qualifies for these treatments.

What are SGLT2 inhibitors, and why were they used in diabetes?

SGLT2 stands for sodium-glucose cotransporter 2 — a protein in the kidney's filtering tubes that reabsorbs glucose back into the bloodstream instead of letting it spill into urine. In people with type 2 diabetes, blocking this protein forces excess glucose out through the urine, which lowers blood sugar. The three most widely prescribed drugs in this class are dapagliflozin (Farxiga), empagliflozin (Jardiance), and canagliflozin (Invokana).

When cardiovascular safety trials for these drugs were conducted starting around 2015, researchers noticed something unexpected: patients taking SGLT2 inhibitors had lower rates of kidney function decline than patients on placebo. This wasn't the primary focus of those trials, but the signal was strong enough to prompt dedicated kidney protection studies — and that's what produced the DAPA-CKD trial.

How do they protect the kidney?

The mechanism is distinct from the blood sugar effect. Blocking SGLT2 also reduces the amount of sodium reabsorbed by the kidney's filtering unit (the glomerulus). This triggers a feedback loop — called tubuloglomerular feedback — that causes the tiny blood vessel feeding each glomerulus to constrict slightly. The result is lower pressure inside the glomerulus itself.

This matters because CKD with protein in the urine (albuminuria) is largely driven by that elevated intraglomerular pressure. The kidney's filtering barrier is under physical stress, and proteins that shouldn't cross into the urine start leaking through. Over years, this causes scarring and progressive kidney function loss. By reducing intraglomerular pressure, SGLT2 inhibitors interrupt this cycle — independently of whether blood sugar is elevated or not. The kidney protection mechanism does not require diabetes to work.

What the DAPA-CKD trial showed

The DAPA-CKD trial enrolled 4,304 patients across multiple countries. Eligibility required an estimated glomerular filtration rate (eGFR) between 25 and 75 — meaning participants had moderate-to-severe kidney disease — plus albuminuria of at least 200 mg/g on a urine test. Approximately two-thirds had type 2 diabetes; the remaining one-third did not.

Patients were randomized to dapagliflozin 10 mg once daily or placebo, on top of standard therapy (including ACE inhibitors or ARBs). The primary composite endpoint was a sustained decline in eGFR of at least 50%, end-stage kidney disease (dialysis or transplant), or death from kidney or cardiovascular causes.

The trial was stopped early because the results were so clear. Dapagliflozin reduced the primary endpoint by 39% relative to placebo [2]. The benefit in the non-diabetic subgroup was essentially identical to the benefit in the diabetic group — the drug did not need diabetes to exert its kidney-protective effect. All-cause mortality was also reduced. The safety profile was acceptable, with genital mycotic infections being the most common adverse effect, as expected with this drug class.

Who is a good candidate?

The FDA approved dapagliflozin specifically for CKD in 2021, irrespective of whether the patient has type 2 diabetes. The label indication aligns closely with the DAPA-CKD entry criteria: adults with CKD who have albuminuria.

The key practical criteria are:

• eGFR: The drug is indicated down to an eGFR of 25. Below that threshold, there isn't enough kidney filtration for the drug to be effective or safe. If your eGFR is above 25 and below about 75, you are in the range where the trial showed benefit.
• Albuminuria: The trial required a urine albumin-to-creatinine ratio (uACR) of at least 200 mg/g. Patients with CKD but no significant albuminuria were not studied in DAPA-CKD and are generally not the target population. Albuminuria reflects active kidney stress and is the signature of the patients who benefit most.
• Absence of type 1 diabetes: SGLT2 inhibitors are not approved for type 1 diabetes and carry a risk of diabetic ketoacidosis in that population. DAPA-CKD excluded patients with type 1 diabetes.
• No recurrent urinary tract infections: Frequent UTIs can be worsened by the glucose-in-urine effect. This is a relative contraindication worth discussing with your nephrologist.

What albuminuria means and why it matters

Albuminuria means albumin — a protein that should stay in the blood — is leaking into the urine. It's measured as the albumin-to-creatinine ratio (uACR) on a urine sample, and it's both a marker of kidney damage and a driver of further damage.

Glenn Chertow's landmark 2004 study in the New England Journal of Medicine established just how serious the burden of CKD is at the population level: even mildly reduced GFR was independently associated with substantially increased risk of death, cardiovascular events, and hospitalization [1]. The combination of reduced eGFR and albuminuria compounds that risk. SGLT2 inhibitors address both the kidney progression trajectory and the cardiovascular risk that comes with it.

Richard Lafayette's research at Stanford focuses specifically on proteinuric kidney diseases — conditions like IgA nephropathy, membranous nephropathy, and focal segmental glomerulosclerosis — where albuminuria is the central problem [5, 6]. These are exactly the patients who carry the disease signature (albuminuria plus reduced eGFR) that defined the DAPA-CKD population and who would be most likely to benefit from SGLT2 inhibitor therapy outside the context of diabetes.

At a glance: who benefits from SGLT2 inhibitors in CKD

What to ask your nephrologist

• Do I have albuminuria? What is my uACR result?
• What is my current eGFR, and am I in the range where dapagliflozin is indicated?
• I don't have type 2 diabetes — does that change whether I can take an SGLT2 inhibitor?
• Are there any reasons I'm not currently taking one? Is it a contraindication, or just that it hasn't been discussed?
• Which SGLT2 inhibitor is most appropriate for my specific kidney diagnosis — dapagliflozin, empagliflozin, or canagliflozin?
• If I start one, what side effects should I watch for, and under what circumstances should I temporarily stop taking it (for example, before surgery)?

The bottom line

SGLT2 inhibitors are no longer a diabetes drug class that happens to help kidneys. They are a kidney-protective drug class with a clear FDA indication for CKD — regardless of whether the patient has diabetes. The DAPA-CKD trial showed a 39% relative risk reduction in the composite of severe kidney function decline, kidney failure, and kidney or cardiovascular death, and that benefit held up equally well in the one-third of trial participants who did not have type 2 diabetes [2].

The entry criteria are specific: you need an eGFR between roughly 25 and 75 and meaningful albuminuria (uACR at or above 200 mg/g). If you meet those criteria and you're not on an SGLT2 inhibitor, it is worth raising the question directly with your nephrologist. The evidence is now strong enough — and the FDA indication clear enough — that the absence of diabetes is not a reason to skip this conversation.